The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU ...
Other content in this Stream
Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th fibrosis at the 56th ERA/EDTA congress
Prometic today announced the presentation of three scientific posters on the Company’s lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™.
The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU regulatory agencies.
This initiative, sponsored by Prometic, aims to raise awareness and improve understanding of this rare disease and its effects. Plasminogen Deficiency Awareness Week is a free 4-day online event
Implementation plan for additional analytical assays and in-process controls confirmed and PLI finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing
In a gold-standard animal model proven to emulate pulmonary fibrosis in humans, Prometic’s Plasminogen (Ryplazim™) performed favorably compared to recently- approved IPF drugs to treat this condition.